Ranked #3,763 of 8,699 institutional investors
Artia Global Partners LP
Miami, FL
$471M
US stock portfolio at live prices · today −$3.9M (−0.83%)
Live prices, last trade 10:40 AM ET
- Value at quarter end (Q3 2026)
- $492M
- Change from Q2 2026
- −$34.2M (−6.51%)
- Positions
- 44 · 12 new, 8 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: put options on $3.9M. $57.3M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesINSM 18.4%BTSG 8.25%RVMD 6.56%TRVI 6.36%ARGX 5.93%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| INSM Insmed Incorporated | 589,052 | $86.6M | 18.4% | Unchanged |
| BTSG BrightSpring Health Services, Inc. | 609,944 | $38.8M | 8.25% | Added +18% |
| RVMD Revolution Medicines, Inc. | 185,390 | $30.9M | 6.56% | Unchanged |
| TRVI Trevi Therapeutics, Inc. | 2,210,852 | $30.0M | 6.36% | Unchanged |
| ARGX argenx SE | 29,739 | $27.9M | 5.93% | Unchanged |
| ABVX ABIVAX Société Anonyme | 364,268 | $24.7M | 5.24% | Reduced −29% |
| TVTX Travere Therapeutics, Inc. | 398,493 | $19.4M | 4.12% | Added +18% |
| DGX Quest Diagnostics Incorporated | 65,122 | $16.9M | 3.60% | Unchanged |
| GH Guardant Health, Inc. | 96,704 | $14.0M | 2.97% | Added +154% |
| DNTH Dianthus Therapeutics, Inc. | 165,735 | $13.9M | 2.96% | Added +2% |
| RVTY Revvity, Inc. | 80,948 | $11.9M | 2.53% | New |
| MRK Merck & Co., Inc. | 80,500 | $10.9M | 2.32% | Added +72% |
| JNJ Johnson & Johnson | 27,100 | $7.4M | 1.56% | Added +20% |
| BIIB Biogen Inc. | 29,237 | $7.3M | 1.56% | Added +59% |
| EWTX Edgewise Therapeutics, Inc. | 161,175 | $6.6M | 1.40% | Added +63% |
| BRKR Bruker Corporation | 103,796 | $6.1M | 1.30% | New |
| TMO Thermo Fisher Scientific Inc. | 7,610 | $5.2M | 1.10% | New |
| SRRK Scholar Rock Holding Corporation | 96,285 | $5.0M | 1.05% | Unchanged |
| VKTX Viking Therapeutics, Inc. | 180,731 | $4.6M | 0.98% | Unchanged |
| RAPP Rapport Therapeutics, Inc. | 166,508 | $3.9M | 0.84% | Added +20% |
| CYTK Cytokinetics, Incorporated | 70,700 | $3.7M | 0.80% | Unchanged |
| ABSI Absci Corporation | 464,444 | $3.6M | 0.76% | Unchanged |
| ELVN Enliven Therapeutics, Inc. | 72,100 | $3.4M | 0.72% | Unchanged |
| BLTE Belite Bio, Inc | 24,989 | $3.3M | 0.70% | Unchanged |
| ORKA Oruka Therapeutics, Inc. | 33,400 | $3.2M | 0.68% | Unchanged |
| CELC Celcuity Inc. | 50,522 | $2.8M | 0.59% | Reduced −15% |
| PTGX Protagonist Therapeutics, Inc. | 22,951 | $2.8M | 0.59% | Unchanged |
| UTHR United Therapeutics Corporation | 5,000 | $2.8M | 0.59% | Unchanged |
| GRAL GRAIL, Inc. | 25,200 | $2.6M | 0.54% | New |
| TXG 10x Genomics, Inc. | 46,300 | $2.5M | 0.53% | New |
| MLYS Mineralys Therapeutics, Inc. | 137,800 | $1.9M | 0.41% | Unchanged |
| TWST Twist Bioscience Corporation | 15,300 | $1.6M | 0.34% | New |
| CORT Corcept Therapeutics Incorporated | 18,000 | $1.2M | 0.25% | New |
| A Agilent Technologies, Inc. | 5,800 | $1.0M | 0.21% | New |
| RXRX Recursion Pharmaceuticals, Inc. | 334,402 | $884K | 0.19% | New |
| DRUG Bright Minds Biosciences Inc. | 38,407 | $808K | 0.17% | Unchanged |
| PEPG PepGen Inc. | 205,324 | $784K | 0.17% | Unchanged |
| PRAX Praxis Precision Medicines, Inc. | 2,500 | $768K | 0.16% | Unchanged |
| PROK ProKidney Corp. | 553,744 | $576K | 0.12% | Reduced −69% |
| MBX MBX Biosciences, Inc. | 8,300 | $435K | <0.1% | New |
| SYRE Spyre Therapeutics, Inc. | 4,000 | $386K | <0.1% | Unchanged |
| CLYM Climb Bio Inc | 21,097 | $193K | <0.1% | New |
| DNA Ginkgo Bioworks Holdings, Inc. | 20,444 | $162K | <0.1% | New |
| EYPT EyePoint, Inc. | 464,698 | $119K | <0.1% | Reduced −39% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| IONS Ionis Pharmaceuticals, Inc. | 144,376 | $4.0M |
| XENE Xenon Pharmaceuticals Inc. | 65,000 | $2.4M |
| PALI Palisade Bio, Inc. | 1,992,367 | $1.9M |
| KOD Kodiak Sciences Inc. | 17,019 | $1.7M |
| ALMS Alumis Inc. | 278,546 | $1.2M |
| SION Sionna Therapeutics, Inc. | 119,741 | $350K |
| CMPX Compass Therapeutics, Inc. | 383,200 | $272K |
| TENX Tenax Therapeutics, Inc. | 42,080 | $56K |